Sun Pharmaceutical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve Audited Standalone ....
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharmaceutical Industries has informed the exchanges that a Board meeting is scheduled for 22 May 2026. The meeting will consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and year ended 31 March 2026. Additionally, the Board will consider and recommend a final dividend on equity shares for FY 2025-26, subject to shareholder approval at the ensuing Annual General Meeting. The trading window remains closed from 1 April 2026 until 24 May 2026, which is standard practice ahead of earnings announcements.
This is a routine regulatory intimation; the actual impact on shareholders will depend on the financial results and dividend recommendation disclosed after the meeting. The announcement of a final dividend consideration is generally viewed positively by investors.